Engitix
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
The Westworks 195 Wood Ln Fl 4, London, ...Phone Number
+44 2045307654Website
www.engitix.comRevenue
$14.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Engitix
Founded in 2016, Engitix a British biopharmaceutical company has already developed a platform for discovering human extracellular matrix drug target. Engitix has developed a portfolio of programs in fibrosis and solid tumors and two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform. The company is headquartered in London, United Kingdom.Explore more
Engitix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Engitix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Engitix launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Engitix had a recent Job posting/layoffs
Earning: See what the market has to say on Engitix recently announced quarterly report
Engitix, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Engitix
Funding: Get notified immidiatlly once Engitix has new funding data
Check out if Engitix is spiking on competitors!
Check if Engitix has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Engitix as Masked Content
Find more new buyers
Compare Similar Companies to Engitix
Compare insights from companies similar to Engitix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Engitix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Engitix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Engitix.
Engitix financials insights
Gather financial insights about Engitix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$60.2M
2026
Series A
$25M
Engitix Tech Stack
A closer look at the technologies used by Engitix
Most Recent Scoops
Funding
Funding
Funding
, a biopharmaceutical company, has secured $54 million in additional Series A funding, bringing the round total to $60 million. The round was co-led by Netherton Investments and Dompé farmaceutici S.P.A.
Funding
, a biopharmaceutical company, has secured $54 million in additional Series A funding, bringing the round total to $60 million. The round was co-led by Netherton Investments and Dompé farmaceutici S.P.A.
Funding
Engitix News & Media
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis
Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumorsEngitix appoints two additional international biotech industry leaders as Scientific Advisors
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of two biotech industry leaders as Scientific Advisors: Adrian S. Ray, PhD, and Scott Turner, PhD.Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of Matthew Edwards, Ph.D., as Senior Vice President of Discovery Sciences, and Emma Huang, Ph.D., as Vice President of Data Sciences.Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors, as an independent non-executive director.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Engitix
Sign Up For FreeTo access detailed company insights
Founded in 2016, Engitix a British biopharmaceutical company has already developed a platform for discovering human extracellular matrix drug target. Engitix has developed a portfolio of programs in fibrosis and solid tumors and two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform... Read More
